Abstract
BackgroundTocilizumab (TCZ) is a monoclonal antibody that binds to the interleukin 6 receptor and has shown efficacy in rheumatoid arthritis (RA) patients with different profiles (DMARD failure, monotherapy or anti-TNF...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
